Abstract:Background: Benzodiazepines have long held a leading position in medical therapeutics, known for their multiple common therapeutic properties and primarily being prescribed for anxiety and insomnia. However, their lack of specificity and various side effects have led to a reevaluation of their long-term use, resulting in a rapid growth in the literature focusing on targeted therapies. Areas of uncertainty: Despite many efforts, uncertainties persist and there are heterogeneous findings across studies regarding the pharmacological effects attributed to gamma-aminobutyric acid type A (GABAA) receptor subunits. Selective compounds targeting GABAA receptor alpha subunits are currently under active research and definitive conclusions have not been reached yet. Some compounds have not progressed to clinical trials, while others, if advanced, have been halted. These challenges emphasize the difficulty in translating preclinical findings into clinical use. Data sources: A literature review was conducted using the PubMed database, searching for articles discussing GABAA receptor subunits. The search was refined by including only selective compounds with potential anxiolytic and cognitive enhancement properties. Results: Findings reveal compounds with promising anxiolytic and antidepressant effects with minimal sedation and absence of tolerance development. Moreover, some compounds show potential in alleviating cognitive dysfunction. There is a broad spectrum of potential therapeutic applications for selective compounds, ranging from neurological disorders such as epilepsy and neuropathic pain to cognitive dysfunction-related conditions. Currently, the leading selective compounds with the most promising results in ongoing clinical trials are basmisanil and darigabat. Basmisanil holds further exploration potential in the treatment of cognitive impairment and related conditions, while darigabat shows progress in the advancement of adjunctive therapy of focal onset seizures and for the treatment of panic disorder, respectively. Conclusions: Future drug discovery efforts are encouraged to focus on positive allosteric modulators that selectively target the α2, α3 subunits and negative/positive allosteric modulators that target the α5 subunit of the GABAA receptor. The pursuit of ligands possessing only anxiolytic effects or those enhancing cognition continues to be an important focus for future research, with promising advancements depicted in recent studies.

Pregabalin peptides: conformational comparison of γ3- and γ4-substituted γ-amino acids in αγααα pentapeptides

Synthesis of R‐GABA Derivatives via Pd(II) Catalyzed Enantioselective C(sp3)‐H Arylation and Virtual Validation with GABAB1 Receptor for Potential leads

The Channel-Lining 6′ Amino Acid in the Second Membrane-Spanning Region of Ionotropic GABA Receptors Has More Profound Effects on 4′-Ethynyl-4- N -Propylbicycloorthobenzoate Binding Than the 2′ Amino Acid

[Synthesis of 4-[(4-chlorophenyl) (5-Fluoro-2-hydroxyphenyl) Methylene Amino]butyrates and Its Anticonvulsant Activity].

Discriminative stimulus properties of two training doses of gabapentin in rats: Substitution by pregabalin, diazepam, and pentobarbital.

Targeting GABAAR-Associated Proteins: New Modulators, Labels and Concepts

Heteromeric GABA<sub>A</sub>receptor structures in positively-modulated active states

[The Pharmacology of the GABA-induced Biphasic Response in Guinea-Pig Celiac Ganglion Neurons in Vitro].

Heteromeric GABAA receptor structures in positively-modulated active states

Exploring Various Crystal and Molecular Structures of Gabapentin—A Review

Synthesis and Pharmacological Properties of Novel Esters Based on Monocyclic Terpenes and GABA

GABAA receptor cysteinyl mutants and the ginkgo terpenoid lactones bilobalide and ginkgolides

New Insights Into Pharmacology of GABAA Receptor Alpha Subunits-Selective Modulators

Antibodies against gamma-aminobutyric acid: specificity studies and immunocytochemical results.

New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System

3 β-Methyl-Neurosteroid Analogs Are Preferential Positive Allosteric Modulators and Direct Activators of Extrasynaptic δ-Subunit γ-Aminobutyric Acid Type A Receptors in the Hippocampus Dentate Gyrus Subfield

[Advances in the chemoenzymatic synthesis of gamma-aminobutyric acid derivatives]

An Updated Review on Pharmaceutical Properties of Gamma-Aminobutyric Acid

Molecular dynamics study of structural properties of γ-aminobutyric acid (GABA)

Modular Structure and Polymerization Status of GABAA Receptors Illustrated with EM Analysis and AlphaFold2 Prediction